Pacira Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Pacira Pharmaceuticals's estimated annual revenue is currently $513.3M per year.
- Pacira Pharmaceuticals received $345.0M in venture funding in March 2017. 0
- Pacira Pharmaceuticals's total funding is $112.5M.
- Pacira Pharmaceuticals's current valuation is $2.9B. (January 2022)
Employee Data
- 00
Pacira Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | VP, Commercial-Medical Learning & Development | Reveal Email/Phone |
5 | VP, UK Operations | Reveal Email/Phone |
6 | VP Global Supply Chain | Reveal Email/Phone |
7 | VP Human Resources | Reveal Email/Phone |
8 | VP Investor Relations | Reveal Email/Phone |
9 | SVP, Regulatory Affairs | Reveal Email/Phone |
10 | SVP Finance | Reveal Email/Phone |
Pacira Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 25 | -11% | N/A | N/A |
#2 | $35.8M | 178 | 8% | N/A | N/A |
#3 | $5.4M | 27 | -25% | N/A | N/A |
#4 | $4180M | 14516 | 1% | $550M | N/A |
#5 | $12.5M | 62 | 15% | N/A | N/A |
#6 | $6.7M | 119 | -37% | $199.6M | N/A |
#7 | $9.4M | 47 | 7% | N/A | N/A |
#8 | $10.3M | 51 | 6% | N/A | N/A |
#9 | $106.3M | 529 | 16% | N/A | N/A |
#10 | $15.5M | 77 | 20% | N/A | N/A |
What Is Pacira Pharmaceuticals?
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company dedicated to advancing and improving postsurgical outcomes for acute care practitioners and their patients. The company's flagship product, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com. To see our community guidelines, please visit https://www.pacira.com/Linkedincommunity
keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals
$112.5M
Total Funding
N/A
Number of Employees
$513.3M
Revenue (est)
N/A
Employee Growth %
$2.9B
Valuation
N/A
Accelerator
Pacira Pharmaceuticals News
Antares Pharma, Eli Lily, Galaxo, HMD pharmaceuticals, Inovio Pharmaceuticals, Merck, Novartis, Pacira Pharmaceuticals, Pfizer, Pharmajet,...
Mallinckrodt Pharmaceuticals, Trevena Heron Therapeutics, Pacira BioSciences Pfizer Teva Pharmaceutical Industries Ltd., Eli Lilly & Company...
Pacira Pharmaceuticals. This Exparel Market report covers important market segments on the basis of type, application, and region.
No drugs, opioids or narcotics are used as part of the treatment, which can last up to 90 days before the nerve regenerates. iovera will be added to Pacira’s existing pain management portfolio, which includes Exparel, a bupivacaine-based treatment with proprietary injection technology. Pacira i ...
Pacira Pharmaceuticals, Inc., a San Diego, CA-based acute care specialty pharmaceutical company with a primary focus on formulating, developing and manufacturing sustained-release, injectable products, has received an $11.25m credit facility from GE Capital, Healthcare Financial Services. The f ...
Other Companies in Parsippany
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.2M | 3 | -40% | N/A |
#2 | $0.2M | 3 | 0% | N/A |
#3 | $0.6M | 4 | 0% | N/A |
#4 | $0.4M | 5 | -17% | N/A |
#5 | $0.4M | 5 | 0% | N/A |
Pacira Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2008-11-17 | $85.0M | A | Article | |
| 2010-05-13 | $11.2M | Undisclosed | GE Capital Healthcare Financia | Article |
| 2011-11-17 | $42.3M | Undisclosed | Barclays Capital Inc, Jefferies & Company | Article |
| 2012-05-04 | $27.5M | Unidsclosed | Oxford Finance | Article |
| 2013-01-16 | $100.0M | Undisclosed | Article | |
| 2014-04-09 | $115.0M | Undisclosed | Article | |
| 2017-03-08 | $345.0M | Undisclosed | Article |